Thoracic Aortic Research Center, Policlinico San Donato IRCCS, University of Milan, Milan, Italy.
Prog Cardiovasc Dis. 2013 Jul-Aug;56(1):109-15. doi: 10.1016/j.pcad.2013.05.004. Epub 2013 Jun 4.
Thoracic aortic aneurysm (TAA) is a silent disease, often discovered at a time point that dramatic complications, as rupture and dissection, occur. For the detection of asymptomatic TAA and prevention of such complications, it is essential to have an adequate screening tool. Until now, routine laboratory blood tests have played only a minor role in the screening, diagnosis, tracking and prediction of the natural history of TAAs. However, the knowledge about biomarkers is rapidly expanding in the cardiovascular field, and there are several potential biomarkers that might be implemented into TAA clinical practice in the near future. The most important and promising markers for TAA will be discussed in this overview.
胸主动脉瘤（TAA）是一种无声的疾病，通常在发生破裂和夹层等严重并发症时才被发现。为了检测无症状性 TAA 并预防这些并发症，必须要有一个合适的筛查工具。到目前为止，常规实验室血液检查在 TAA 的筛查、诊断、跟踪和预测自然史方面仅发挥了次要作用。然而，心血管领域的生物标志物知识正在迅速扩展，并且有几个潜在的生物标志物可能在不久的将来应用于 TAA 的临床实践。本篇综述将讨论 TAA 最重要和最有前途的标志物。
